Table 5. Odds ratios1 (ORs) and 95% confidence intervals (95% CIs) for breast cancer associated with AMH concentration by tumor characteristics.
| AMH quartiles2 | Ptrend3 | Pinteraction4 | |||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Q1 | Q2 | Q3 | Q4 | ||||
| Invasiveness | 0.41 | ||||||
| Invasive | Cases/Controls | 508/636 | 547/619 | 564/595 | 636/606 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.19 (0.99, 1.43) | 1.39 (1.14, 1.70) | 1.67 (1.34, 2.09) | <.0001 | ||
| In situ | Cases/Controls | 122/153 | 136/156 | 147/184 | 172/169 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.19 (0.79, 1.79) | 1.10 (0.72, 1.69) | 1.35 (0.85, 2.13) | 0.25 | ||
| ER status | 0.21 | ||||||
| ER+ | Cases/Controls | 324/438 | 353/424 | 377/411 | 441/439 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.27 (1.01, 1.60) | 1.52 (1.19, 1.96) | 1.74 (1.33, 2.28) | <.0001 | ||
| ER- | Cases/Controls | 84/90 | 93/108 | 91/109 | 112/110 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 0.95 (0.60, 1.52) | 1.02 (0.62, 1.69) | 1.17 (0.68, 2.01) | 0.54 | ||
| PR status | 0.02 | ||||||
| PR+ | Cases/Controls | 266/374 | 304/372 | 334/369 | 405/390 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.29 (1.00, 1.65) | 1.61 (1.23, 2.11) | 1.97 (1.48, 2.64) | <.0001 | ||
| PR- | Cases/Controls | 142/154 | 142/160 | 134/151 | 148/159 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 0.96 (0.67, 1.39) | 0.99 (0.66, 1.49) | 1.00 (0.65, 1.55) | 0.95 | ||
| HER2 status | 0.37 | ||||||
| HER2+ | Cases/Controls | 44/60 | 44/55 | 38/62 | 80/57 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.11 (0.58, 2.11) | 1.17 (0.57, 2.44) | 3.39 (1.55, 7.42) | 0.002 | ||
| HER2- | Cases/Controls | 182/275 | 227/280 | 244/263 | 266/279 | . | |
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.36 (1.01, 1.83) | 1.80 (1.31, 2.48) | 2.05 (1.45, 2.92) | <.0001 | ||
| Joint receptor status | |||||||
| ER+/PR+ | Cases/Controls | 259/360 | 288/358 | 317/354 | 386/371 | 0.15 | |
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.26 (0.97, 1.62) | 1.58 (1.20, 2.08) | 1.96 (1.46, 2.64) | <.0001 | ||
| ER+/PR- | Cases/Controls | 65/78 | 65/66 | 60/57 | 55/68 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 1.25 (0.68, 2.28) | 1.13 (0.58, 2.19) | 0.82 (0.40, 1.68) | 0.51 | ||
| ER-/PR+ | Cases/Controls | 7/14 | 16/14 | 17/15 | 19/19 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 3.10 (0.60, 15.9) | 3.53 (0.60, 20.8) | 3.23 (0.48, 21.9) | 0.26 | ||
| ER-/PR- | Cases/Controls | 77/76 | 77/94 | 74/94 | 93/91 | ||
| Adjusted OR (95% CI) | 1.00 (Referent) | 0.83 (0.50, 1.39) | 0.90 (0.51, 1.58) | 1.15 (0.63, 2.09) | 0.60 | ||
| Triple-negative (ER-/PR-/HER2-) tumors | |||||||
| Cases/Controls | 29/28 | 25/35 | 28/29 | 33/42 | |||
| Adjusted OR (95% CI) | 1.00 (Referent) | 0.84 (0.31, 2.28) | 1.17 (0.41, 3.37) | 1.02 (0.34, 3.04) | 0.95 | ||
Estimated using conditional logistic regression model and adjusting for race/ethnicity (white, black, other or unknown), education (high school or less, some college or higher, unknown), BMI (<18.5, 18.5-25, 25-30, 30+ kg/m2), age at menarche (ordered categorical, <12, 12, 13, 14+ years), parity (ordered categorical, 0, 1, 2, 3+), age at 1st FTP (ordered categorical, <=20, 21-25, 26-30, 30+ years or nulliparous), oral contraceptive use (never, former, current, unknown), partial oophorectomy (no, yes, unknown), family history of breast cancer (no, yes), benign breast biopsy (no, yes, unknown), and smoking status (never, former, current, unknown).
Defined using cohort-specific cutpoints.
Ptrend was calculated using ordered categorical AMH.
Pinteraction was calculated by including an interaction term between AMH (ordered categorical) and each tumor characteristic.